Corrigendum to "Cytokine profiles in pemphigus vulgaris patients treated with intravenous immunoglobulins as compared to conventional immunosuppressive therapy" [Cytokine 41 (2008) 315-321] (DOI:10.1016/j.cyto.2007.12.007);Cytokine profiles in pemphigus vulgaris patients treated with intravenous immunoglobulins as compared to conventional immunosuppressive therapy

Cytokine

Volumn 41, Issue 3, 2008, Pages 315-321

  Keskin, Derin B ^a   Stern, Joel N H ^a,b   Fridkis Hareli, Masha ^a   Razzaque Ahmed, A ^c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^c NEW ENGLAND BAPTIST HOSPITAL   (United States)

Author keywords

Clinical course; Conventional immunosuppressive therapy; Cytokine and chemokine profiles; Intravenous immunoglobulin; Pemphigus vulgaris

Indexed keywords

CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DATA COLLECTION METHOD; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; MALE; PEMPHIGUS VULGARIS; PRIORITY JOURNAL;

EID: 39749119781     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2008.05.014     Document Type: Erratum

References (71)

1. W.F. Lever Pemphigus and pemphigoid J Am Acad Dermatol 1 1979 2 31
2. C. Scully A review of mucocutaneous disorders affecting the mouth and lips Ann Acad Med Singapore 28 1999 704 707
3. J.E. Scott A.R. Ahmed The blistering diseases Med Clin North Am 82 1998 1239 1283
4. H.C. Nousari G.J. Anhalt Pemphigus and bullous pemphigoid Lancet 354 1999 667 672
5. N. Korman Pemphigus J Am Acad Dermatol 18 1998 1219 1238
6. Z. Tehranchi-Nia T.A. Qureshi A.R. Ahmed Pemphigus vulgaris in older adults J Am Geriatr Soc 461 1998 92 94
7. D.G. Simon D. Krutchkoff R.A. Kaslow R. Zarbo Pemphigus in Hartford County, Connecticut, from 1972 to 1977 Arch Dermatol 1169 1980 1035 1037
8. J. Hietanen O.P. Salo Pemphigus: an epidemiological study of patients treated in Finnish hospitals between 1969 and 1978 Acta Derm Venerol 62 1982 491 496
9. A.T. Goon S.H. Tan Comparative study of pemphigus vulgaris and pemphigus foliaceus in Singapore Australas J Dermatol 42 2001 172 175
10. E. Hernandez-Perez Pemphigus in El Salvador. An eight-year study (1970–1977) Int J Dermatol 18 1979 645 648
11. S. Pisanti Y. Sharav E. Kaufman L.N. Posner Pemphigus vulgaris: incidence in Jews of different ethnic groups, according to age, sex, and initial lesion Oral Surg Oral Med Oral Pathol 38 1974 382 387
12. M.C. Udey J.R. Stanley Pemphigus diseases of anti-desmosomal autoimmunity JAMA 282 1999 572 576
13. J.R. Stanley Pemphigus I.M. Freedberg A.Z. Eisen K. Wolff K.F. Austen L.A. Goldsmith S.I. Katz Fitzpatrick’s Dermatology in General Medicine 2003 McGraw-Hill 558 566
14. G.G. Toth M.F. Jonkman Therapy of pemphigus Clin Dermatol 19 2001 761 767
15. C.S. Foster A.R. Ahmed Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study Ophthalmology 106 1999 2136 2143
16. T.E. Fleming N.J. Korman Cicatricial pemphigoid J Am Acad Dermatol 43 2000 571 591
17. J.P. Dutz V.C. Ho Immunosuppressive agents in dermatology. An update Dermatol Clin 16 1998 235 251
18. A.R. Ahmed Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment J Am Acad Dermatol 45 2001 679 690
19. W. Aberer E.C. Wolff-Schreiner G. Stingl K. Wolff Azathioprine in the treatment of pemphigus vulgaris: a long-term follow-up J Am Acad Dermatol 16 1987 527 533
20. A.R. Ahmed S. Hombal Use of cyclophosphamide in azathioprine failures in pemphigus J Am Acad Dermatol 17 1987 437 442
21. Y. Poulin H.O. Perry A.S. Muller Pemphigus vulgaris: results of treatment with gold as a steroid sparing agent in a series of thirteen patients J Am Acad Dermatol 11 1984 851 857
22. A.G. Pandya C. Dyke Treatment of pemphigus with gold Arch Dermatol 134 1988 1104 1107
23. T.J. Smith J.C. Bystryn Methotrexate as an adjuvant treatment for pemphigus vulgaris Arch Dermatol 135 1999 1275 1276
24. N. Shah A.R. Green G.W. Elgart F. Kerdel The use of chlorambucil with prednisone in the treatment of pemphigus J Am Acad Dermatol 42 2000 85 88
25. M. Lapidoth M. David D. Ben-Amitai V. Katzenelson S. Lustig M. Sandbank The efficacy of combined treatment with prednisone and cyclosporine in patients with pemphigus: preliminary study J Am Acad Dermatol 30 1994 752 757
26. H. Barthelemy A. Frappaz F. Cambazard G. Mauduit B. Rouchouse J. Kanitakis Treatment of nine cases of pemphigus vulgaris with cyclosporine J Am Acad Dermatol 18 1988 1262 1266
27. N. Sato S. Satake H. Fujiwara M. Ito K. Kameda E. Nagahori Pemphigus vulgaris treated with combined oral cyclosporin and cyclophosphamide Clin Exp Dermatol 23 1998 92 94
28. M. Grundmann-Kollmann H.C. Korting S. Behrens U. Leiter G. Krähn R. Kaufmann Successful treatment of severe refractory atopic dermatitis with mycophenolate mofetil Br J Dermatol 141 1999 175 176
29. N. Basset B. Guillot B. Michael J. Meynadier J.J. Guilhou Dapsone as initial treatment in superficial pemphigus: report of nine cases Arch Dermatol 123 1987 783 785
30. A. Calebotta A.M. Saenz F. Gonzalez M. Carvalho R. Castillo Pemphigus vulgaris: benefits of tetracycline as adjuvant therapy in a series of thirteen patients Int J Dermatol 38 1999 217 221
31. Z.S. Gaspar V. Walkden F. Wojnarowska Minocycline is a useful adjuvant therapy of pemphigus Australas J Dermatol 37 1996 93 95
32. J.C. Bystryn N.M. Steinman The adjuvant therapy of pemphigus Arch Dermatol 132 1996 203 212
33. F. Chryssomallis A. Dimitriades G.C. Chaidemenos D. Panagiotides G. Karakatsanis Steroid-pulse therapy in pemphigus vulgaris long term follow-up Int J Dermatol 34 1995 438 442
34. J.S. Pasricha B.K. Khaitan R.S. Raman M. Chandra Dexamethasone-cyclophosphamide pulse therapy for pemphigus Int J Dermatol 34 1995 875 882 1995
35. J.C. Guillaume J.C. Roujeau P. Morel M.S. Doutre B. Guillot D. Lambert Controlled study of plasma exchange in pemphigus Arch Dermatol 124 1988 1659 1663
36. K. Sondergaard J. Carstens J. Jorgensen H. Zachariae The steroid-sparing effect of long-term plasmapheresis in pemphigus Acta Derm Venereol 75 1995 150 152
37. U. Wollina D. Lange A. Looks Short-time extracorporeal photochemotherapy in the treatment of drug-resistant autoimmune bullous diseases Dermatology 198 1999 140 144
38. L. Engineer K.C. Bhol A.R. Ahmed Analysis of current data on the use of intravenous immunoglobulins in management of pemphigus vulgaris J Am Acad Dermatol 43 2000 1049 1057
39. M.D. Kazatchkine S.V. Kaveri Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin N Engl J Med 345 2001 747 755
40. A.R. Ahmed Use of intravenous immunoglobulin therapy in autoimmune blistering diseases Int Immunopharmacol 6 2006 557 578
41. J. Bayary S. Dasgupta N. Misra A. Ephrem J.P. Duong Van Huyen S. Delignat Intravenous immunoglobulin in autoimmune disorders: an insight into the immunoregulatory mechanisms Int Immunopharmacol 6 2006 528 534
42. U.G. Andersson L. Bjork S.U. Skansen J.P. Andersson Pooled human IgG modulates cytokine production in lymphocytes and monocytes Immunol Rev 139 1994 21 42
43. M.C. Dalakas Intravenous immune globulin therapy for neurologic diseases Ann Intern Med 126 1997 721 730
44. K.C. Bhol A. Desai S. Kumari J.E. Colon A.R. Ahmed Pemphigus vulgaris: the role of IL-1 and IL-1 receptor antagonist in pathogenesis and effects of intravenous immunoglobulin on their production Clin Immunol 100 2001 172 180
45. V. Ruiz de Souza M.P. Carreno S.V. Kaveri A. Ledur H. Sadeghi J.M. Cavaillon Selective induction of interleukin-1 receptor antagonist and interleukin-8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin) Eur J Immunol 25 1995 1267 1273
46. M. Sharief D. Ingram M.E. Swash IV immunoglobulin reduces circulating proinflammatory cytokines in Guillain–Barre syndrome Neurology 52 1999 1833 1838
47. L. D’Auria C. Bonifati A. Mussi g. D’Agosto C. DeSimone B. Giacalone Cytokines in the sera of patients with pemphigus vulgaris: interleukin-6 and tumor necrosis factor-alpha levels are significantly increased as compared to healthy subjects and correlate with disease activity Eur Cytokine Netw 8 1997 383 387
48. L. D’Auria C. Bonifati P. Cordiali-Fei G. Leone M. Picaro M. Pietravalle Increased serum interleukin-15 levels in bullous skin diseases: correlation with disease intensity Arch Dermatol Res 291 1999 354 356
49. A. Baroni B. Perfetto E. Ruocco R. Greco D. Criscuolo V. Ruocco Cytokine pattern in blister fluid and sera of patients with pemphigus Dermatology 205 2002 116 121
50. K.C. Bhol A.I. Rojas I.U. Khan A.R. Ahmed Presence of interleukin 10 in the serum and blister fluid of patients with pemphigus vulgaris and pemphigoid Cytokine 12 2000 1076 1083
51. C. Feliciani P. Toto P. Amerio S.M. Pour G. Coscione G. Shivji In vitro and in vivo expression of interleukin-1alpha and tumor necrosis factor-alpha mRNA in pemphigus vulgaris: interleukin-1alpha and tumor necrosis factor-alpha are involved in acantholysis J Invest Dermatol 114 2000 71 77
52. A.R. Ahmed R. Moy Death in pemphigus J Am Acad Dermatol 7 1982 221 228
53. A. Herbst J.C. Bystryn Patterns of remission in pemphigus vulgaris J Am Acad Dermatol 42 2000 422 427
54. J.J. Marchalonis H. Kaymaz F. Dedeoglu S.F. Schlutter D.E. Yocum A.B. Edmundson Human autoantibodies reactive with synthetic autoantigens from T-cell receptor β chain Proc Natl Acad Sci USA 89 1992 3325 3329
55. M. Svenson M.B. Hansen C. Ross M. Diamant K. Rieneck H. Nielsen Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in human IgG preparations Blood 91 1998 2054 2061
56. K. Bendtzen M.B. Hansen C. Ross M. Svenson High-avidity autoantibodies to cytokines Immunol Today 19 1998 209 211
57. T. Vassilev C. Gelin S.V. Kaveri M.T. Zilber L. Boumsell M.D. Kazatchkine Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg) Clin Exp Immunol 92 1993 369 372
58. V. Hurez S.V. Kaveri A. Mouhoub G. Dietrich J.C. Mani D. Klatzmann Anti-CD4 activity of normal human immunoglobulins G for therapeutic use (intravenous immunoglobulin, IVIg) Ther Immunol 1 1994 269 278
59. S. Kaveri T. Vassilev V. Hurez R. Lengagne S. Cot P. Pouletty Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use (IVIg) J Clin Invest 97 1996 865 869
60. T. Vassilev M.D. Kazatchkine J.P. Duong Van Huyen M. Mekrache E. Bonnin D. Korinth Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg) Blood 93 1999 3624 3631
61. H. Bouhlal H. Hocini C. Quillent-Gregoire V. Donkova S. Rose A. Amara Antibodies to C–C chemokine receptor 5 in normal human IgG block infection of macrophages and lymphocytes with primary R5-tropic strains of HIV-1 J Immunol 166 2001 7606 7611
62. J. Bayry S. Lacroix-Desmazes V. Donkova C. Carboneil N. Misra Y. Lepelletier Natural antibodies sustain differentiation and maturation of human dendritic cells Proc Natl Acad Sci USA 101 2004 14210 14215
63. N. Prasad G. Papoff A. Zeuner E. Bonnin M.D. Kazatchkine G. Ruberti Therapeutic preparations of normal polyspecific immunoglobulin G (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway J Immunol 161 1998 3781 3790
64. I. Viard P. Wehrli R. Bullani P. Schneider N. Holler D. Salomon Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin Science 282 1998 490 493
65. F. Altznauer S. von Gunten P. Spath H.U. Simon Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations J Allergy Clin Immunol 112 2003 1185 1190
66. N. Sooryanarayana E. Prasad A. Bonnin K. Pashov K. Ben-Jilani J.C. Ameisen Phosphorylation of Bcl-2 and mitochondrial changes are associated with apoptosis of lymphoblastoid cells induced by normal immunoglobulin Biochem Biophys Res Commun 264 1999 896 901
67. J. Bayry S. Lacroix-Desmazes C. Carbonneil N. Misra V. Donkova A. Pashov Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin Blood 101 2003 758 765
68. R.M. Steinman I. Mellman Immunotherapy: bewitched, bothered, and bewildered no more Science 305 2004 197 200
69. J. Bayry S. Lacroix-Desmazes M.D. Kazatchkine S.V. Kaveri Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action Nat Clin Pract Rheumatol 5 2007 262 272
70. A.R. Ahmed Z. Spigelman L.A. Cavacini M.R. Posner Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin N Engl J Med 17 2006 1772 1779
71. J. Bayry M.D. Kazatchkine S.V. Kaveri Shortage of human intravenous immunoglobulin—reasons and possible solutions Nat Clin Pract Neurol 3 2007 120 121